Literature DB >> 12189649

Mucopolysaccharidosis type I: Identification and characterization of mutations affecting alpha-L-iduronidase activity.

Guey-Jen Lee-Chen1, Shuan-Pei Lin, I-Shen Chen, Jui-Hung Chang, Chyau-Wen Yang, Yi-Wen Chin.   

Abstract

Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). MPS I covers a broad spectrum of clinical severity ranging from severe Hurler syndrome through intermediate Hurler/Scheie syndrome to mild Scheie syndrome. Mutation screening was performed in two unrelated Taiwanese MPS I patients. A Hurler/Scheie patient had A79V (C to T transition in codon 79) in exon 2 and R619G (C to G transversion in codon 619) in exon 14. R619G has been shown to cause disease. Expression of A79V in COS-7 cells showed trace amounts of IDUA activity, demonstrating the deleterious nature of the mutation. A79V mutation did not cause a reduction in IDUA mRNA levels. The reduced level of IDUA protein suggests increased degradation of the mutant enzyme. A Hurler patient had 134del12 (in-frame deletion of codons 16-19 in signal peptide) in exon 1 and Q584X (C to T transition in codon 584) in exon 13. Transfection of COS-7 cells with Q584X did not yield active enzyme. Q584X mutation caused an apparent reduction in the IDUA mRNA level and no IDUA protein was detected. Conversely, 134del12 showed 124.6% of normal activity in transfected cells and a 77-kDa precursor protein was observed on Western blot, suggesting biologic activity of precursor IDUA without posttranslational cleavage. These findings provide further evidence of the molecular heterogeneity in mutations in MPS I.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189649

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

1.  Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.

Authors:  H-Y Lin; S-P Lin; C-K Chuang; M-R Chen; B-F Chen; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  A Novel Frameshift Mutation Associated with Hurler's Syndrome: A Case Report.

Authors:  Mana Kamranjam; Seyedeh Maryam Hosseini; Mohammadreza Alaei
Journal:  J Pediatr Genet       Date:  2019-04-03

3.  Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families.

Authors:  Luning Sun; Chunyi Li; Xiaoyu Song; Ningning Zheng; Haipeng Zhang; Guizhang Dong
Journal:  Genet Mol Biol       Date:  2011-04-01       Impact factor: 1.771

4.  Novel frameshift variant in the IDUA gene underlies Mucopolysaccharidoses type I in a consanguineous Yemeni pedigree.

Authors:  Belal Azab; Zain Dardas; Mohannad Hamarsheh; Mohammad Alsalem; Zaid Kilani; Farah Kilani; Abdalla Awidi; Hanan Jafar; Sami Amr
Journal:  Mol Genet Metab Rep       Date:  2017-06-09

5.  Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.

Authors:  Chih-Kuang Chuang; Hsiang-Yu Lin; Tuan-Jen Wang; You-Hsin Huang; Min-Ju Chan; Hsuan-Chieh Liao; Yun-Ting Lo; Li-Yun Wang; Ru-Yi Tu; Yi-Ya Fang; Tzu-Lin Chen; Hui-Chen Ho; Chuan-Chi Chiang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2018-05-25       Impact factor: 4.123

6.  Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I.

Authors:  Arunabha Ghosh; Aiyin Liao; Claire O'Leary; Jean Mercer; Karen Tylee; Anu Goenka; Rebecca Holley; Simon A Jones; Brian W Bigger
Journal:  Mol Ther Methods Clin Dev       Date:  2019-03-02       Impact factor: 6.698

7.  Mucopolysaccharidosis type I in 21 Czech and Slovak patients: mutation analysis suggests a functional importance of C-terminus of the IDUA protein.

Authors:  Alzbeta Vazna; Clare Beesley; Linda Berna; Larisa Stolnaja; Helena Myskova; Michaela Bouckova; Hana Vlaskova; Helena Poupetova; Jiri Zeman; Martin Magner; Anna Hlavata; Bryan Winchester; Martin Hrebicek; Lenka Dvorakova
Journal:  Am J Med Genet A       Date:  2009-05       Impact factor: 2.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.